What is it about?
This review discussed the mechanisms involved in DR, a novel diagnostic tool, and recent findings of new therapeutics such as incretin-based therapy, SGLT-2 inhibitors, and nsMRA.
Featured Image
Photo by Helena Lopes on Unsplash
Why is it important?
Diabetic microvascular complications can affect patients earlier than macrovascular issues, like diabetic retinopathy, and often impact their quality of life. But beyond just lowering blood sugar, protecting these small vessels and evaluating their function might be even more crucial in preventing microvascular problems like DR. New diabetic medications such as GLP-1, SGLT-2, and nsMRA could have extra benefits for DR. Therefore, understanding and figuring out the best treatments, including possible combinations, could be really important.
Perspectives
Besides protecting against macrovascular complications demonstrated by CVOTs, it also seems important to alleviate the effects of microvascular complications. It is encouraging to see that additional protection from novel medications could reduce the more frequent microvascular complications and improve quality of life.
Dr. Song Wen
Shanghai Pudong Hospital, Fudan University
Read the Original
This page is a summary of: The novel antidiabetic medications on diabetic retinopathy: relevant molecular mechanisms, advancing diagnostic innovations, and therapeutic implications, Frontiers in Medicine, January 2026, Frontiers,
DOI: 10.3389/fmed.2025.1670643.
You can read the full text:
Resources
Contributors
The following have contributed to this page
